CCR2 and neoplasm: In addition to enhancing tumor-specific cytotoxic T cell responses, future immunotherapeutic approaches may need to focus on the immunosuppressive TME, including the role of CCR2+ monocytes, and the interplay with IFN-γ and IL-6 in HNSCC and the patients’ blood.